search
Back to results

A Study to Determine the Effect of Triheptanoin Compared With Even-chain, MCT on MCEs in Pediatric Patients With LC-FAOD

Primary Purpose

Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Triheptanoin
MCT Oil
Sponsored by
Ultragenyx Pharmaceutical Inc
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) focused on measuring Carnitine Palmitoyl Transferase (CPT) I Deficiency, Carnitine Palmitoyl Transferase (CPT) II Deficiency, Carnitine/acylcarnitine Translocase (CACT) Deficiency, Very Long Chain Acyl-coenzyme A Dehydrogenase (VLCAD) Deficiency, Long-chain 3-hydroxyacyl-coenzyme A Dehydrogenase (LCHAD) Deficiency, Mitochondrial Trifunctional Protein (TFP) Deficiency

Eligibility Criteria

undefined - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria for Main Study: Males and females, from 0 (including newborns) to < 18 years of age Confirmed diagnosis of LC-FAOD Have a caregiver(s) willing and able to assist in all applicable study requirements Have a legally authorized representative willing and able to provide written informed consent after the nature of the study has been explained and prior to any research-related procedures, and the study participant to be able to provide age-appropriate written assent Have ANY ONE of the following significant clinical manifestations of LC-FAOD: At least 2 in the prior year, or 3 in the prior 2 years, of severe major episodes of metabolic decompensation (eg, hypoglycemia, rhabdomyolysis, or exacerbation of cardiomyopathy, requiring ER/urgent care unit visits or hospitalizations) Recurrent symptomatic hypoglycemia (clinical symptoms of hypoglycemia) requiring intervention Susceptibility to hypoglycemia after short periods of fasting (less than 4 to 12 hours, depending on age) Evidence of functional cardiomyopathy requiring ongoing medical management or clinical manifestation of heart failure Sibling(s) with the same pathogenic variant who presented with MCEs Participant with pathogenic variants that are known or suspected to be associated with absent or severely reduced enzyme activity or with severe disease manifestations. From the time of informed consent to 5 days after the last dose of study drug in this study, females of childbearing potential and fertile males must consent to use highly effective methods of contraception. If female, agree not to become pregnant. If male, agree not father a child or donate sperm Inclusion Criteria for Liver Substudy: Enrollment in the Main Study of Study UX007-CL302 Age > 2 years Liver fat content ≥ 2% and < 20% PDFF as assessed by 1 H-MRS Body mass index < 95th percentile Able to comply with instructions (remaining still during scan) and requirements (eg, constraints on recent meals, no metallic items or implanted devices in the body, no recent contrast agents) for liver 1 H-MRS scan Exclusion Criteria for Main Study: Enrolled in a clinical study involving concurrent use of an investigational drug product within 30 days before Screening Use of a prohibited medication (eg, valproate products or pancreatic lipase inhibitors) within 30 days before Screening, or unwilling to avoid a prohibited medication or other substance that may confound study objectives Treatment with triheptanoin within 60 days of Screening History of known hypersensitivity to triheptanoin or MCT Caregiver unwilling or unable to sign informed consent, or release of medical records, or follow study procedures Have any co-morbid conditions, including unstable major organ-system disease(s) that in the opinion of the Investigator places the subject at increased risk of complications, interferes with study participation or compliance, or confounds study objectives. History of metabolic decompensation(s) with metabolic acidosis, hyperammonemia, and/or liver enzyme elevations does not constitute an exclusion criterion unless in the opinion of the Investigator places the subject at increased risk of complications, interferes with study participation or compliance, or confounds study objectives Have a diagnosis of pancreatic insufficiency Pregnant, breastfeeding, or planning to become pregnant (self or partner) at any time during the study Exclusion Criteria for Liver Substudy: Acute or chronic liver disease other than LC-FAOD that presents with increased risk of liver fat (eg, hepatic cirrhosis, viral toxic or drug hepatitis, diabetes mellitus) and/or metabolic syndrome Need for anesthesia/sedation to perform liver 1 H-MRS

Sites / Locations

  • General University Hospital in Prague-GUH (Všeobecná fakultní nemocnice v Praze- VFN)Recruiting
  • Universität FreiburgRecruiting
  • Instytut Pomnik-Centrum Zdrowia Dziecka
  • Gdańksi Uniwersytet MedycznyRecruiting
  • King Faisal Specialist Hospital & Research Centre
  • Sant Joan de Deu Hospital (SJD)Recruiting
  • University Hospital Santiago de CompostelaRecruiting
  • University Hospital 12 de OctubreRecruiting
  • Gazi UniversityRecruiting
  • Ege UniversityRecruiting
  • Istanbul Universitesi Istanbul Tip Fakultesi HastanesiRecruiting
  • Cerrahpasa Medical FacultyRecruiting
  • Great Ormond Street HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Triheptanoin

MCT

Arm Description

Participants will be given prescriptions for Triheptanoin in mL/day, which will be divided into approximately 4 administrations per day, with precise instructions for administration. Triheptanoin will be titrated up to the first 6 weeks of the study. After titration, the dose is to remain stable for the remainder of the Double-blind Treatment Period.

Participants will be given prescriptions for MCT in mL/day, which will be divided into approximately 4 administrations per day, with precise instructions for administration. MCT will be titrated up to the first 6 weeks of the study. After titration, the dose is to remain stable for the remainder of the Double-blind Treatment Period.

Outcomes

Primary Outcome Measures

Annualized Event Rate of Major Clinical Events (MCEs) During the Double-blind Treatment Period

Secondary Outcome Measures

Annualized Duration of MCEs During the Double-blind Treatment Period
Annualized Hypoglycemic Event-rate Captured as MCEs and/or At-home Clinical Events (HCEs) During the Double-blind Treatment Period
Clinician-reported Change in Global Impression of Disease Severity (Clinical Global Impression of Change [CGI-C] Scale) Score at End of Study (EOS)
Change From Baseline in Left Ventricular Ejection Fraction
Change From Baseline in Left Ventricular Systolic Volume
Change From Baseline in Left Ventricular Wall Mass
Liver Substudy (Single Study Site Only): Change from Baseline to 6 Months in Hepatic Proton Density Fat Fraction (PDFF%), Assessed by 1H-Magnetic Resonance Spectroscopy (1H-MRS)
Liver Substudy (Single Study Site Only): Change From Baseline to 6 Months in Creatine Kinase/Alanine Aminotransferase (CK/ALT)
Liver Substudy (Single Study Site Only): Change From Baseline to 6 Months in Alanine Aminotransferase (ALT)
Liver Substudy (Single Study Site Only): Change From Baseline to 6 Months in Aspartate Aminotransferase (AST)
Annualized Frequency of Rhabdomyolysis and Cardiomyopathy-MCEs During the Double-blind Treatment Period
Annualized Duration of Rhabdomyolysis, Cardiomyopathy, and Hypoglycemic-MCEs During the Double-blind Treatment Period
Change From Baseline to EOS in Caregiver-reported Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scale Score for Participants 2 Years of Age or Older
Change From Baseline to EOS in PedsQL Infant Scale Score for Participants Ages 1 to <24 Months
Survival Time During the Double-blind Treatment Period
Annualized Hospitalization Days During the Double-blind Treatment Period
Number of Missed School or Learning Opportunity Days During the Double-blind Treatment Period
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, and Adverse Events of Special Interest (AESIs)
Number of Participants With TEAEs and Serious TEAEs Leading to Dose Modifications, Dose Reductions, Treatment Interruptions, Discontinuations From Study Drug, and Discontinuations From the Study
Plasma Concentration Levels of Heptanoate
Plasma Concentration Levels of Beta Hydroxypentanoate (BHP)
Acceptability and Palatability Survey Scores of Triheptanoin Mixed with Oral Liquids

Full Information

First Posted
June 27, 2023
Last Updated
September 26, 2023
Sponsor
Ultragenyx Pharmaceutical Inc
search

1. Study Identification

Unique Protocol Identification Number
NCT05933200
Brief Title
A Study to Determine the Effect of Triheptanoin Compared With Even-chain, MCT on MCEs in Pediatric Patients With LC-FAOD
Official Title
A Randomized, Double-blind, Multicenter Study to Determine the Effect of Triheptanoin Compared With Even-chain, Medium-chain Triglycerides (MCT) on Major Clinical Events (MCEs) in Pediatric Patients With Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 28, 2023 (Actual)
Primary Completion Date
September 2026 (Anticipated)
Study Completion Date
September 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ultragenyx Pharmaceutical Inc

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The main goal of this study is to evaluate the effects of triheptanoin versus Medium-chain Triglycerides (MCT) on frequency of Major Clinical Events (MCEs).
Detailed Description
Participants will be randomly assigned 1:1 to receive triheptanoin or MCT oil. The duration of the study, which is estimated to be 3.5 to 4 years and comprises of the following: Screening Period, Baseline (Month 0), Double-blind Treatment Period (including Titration and End of Study Visit), and Safety Follow-up Phone Visit. In addition, a substudy will examine the effect of triheptanoin versus MCT on decreasing hepatic lipid content to avoid or improve steatosis in subjects with LC-FAOD. Participants older than 2 years of age at selected sites will be invited to screen for the Liver Substudy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Keywords
Carnitine Palmitoyl Transferase (CPT) I Deficiency, Carnitine Palmitoyl Transferase (CPT) II Deficiency, Carnitine/acylcarnitine Translocase (CACT) Deficiency, Very Long Chain Acyl-coenzyme A Dehydrogenase (VLCAD) Deficiency, Long-chain 3-hydroxyacyl-coenzyme A Dehydrogenase (LCHAD) Deficiency, Mitochondrial Trifunctional Protein (TFP) Deficiency

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Triheptanoin
Arm Type
Experimental
Arm Description
Participants will be given prescriptions for Triheptanoin in mL/day, which will be divided into approximately 4 administrations per day, with precise instructions for administration. Triheptanoin will be titrated up to the first 6 weeks of the study. After titration, the dose is to remain stable for the remainder of the Double-blind Treatment Period.
Arm Title
MCT
Arm Type
Active Comparator
Arm Description
Participants will be given prescriptions for MCT in mL/day, which will be divided into approximately 4 administrations per day, with precise instructions for administration. MCT will be titrated up to the first 6 weeks of the study. After titration, the dose is to remain stable for the remainder of the Double-blind Treatment Period.
Intervention Type
Drug
Intervention Name(s)
Triheptanoin
Other Intervention Name(s)
UX007, Dojolvi
Intervention Description
Liquid for oral (PO) or enteral feeding tube administration
Intervention Type
Dietary Supplement
Intervention Name(s)
MCT Oil
Other Intervention Name(s)
Medium-chain Triglyceride
Intervention Description
Liquid for oral (PO) or enteral feeding tube administration
Primary Outcome Measure Information:
Title
Annualized Event Rate of Major Clinical Events (MCEs) During the Double-blind Treatment Period
Time Frame
Up to Year 4
Secondary Outcome Measure Information:
Title
Annualized Duration of MCEs During the Double-blind Treatment Period
Time Frame
Up to Year 4
Title
Annualized Hypoglycemic Event-rate Captured as MCEs and/or At-home Clinical Events (HCEs) During the Double-blind Treatment Period
Time Frame
Up to Year 4
Title
Clinician-reported Change in Global Impression of Disease Severity (Clinical Global Impression of Change [CGI-C] Scale) Score at End of Study (EOS)
Time Frame
Up to Year 4
Title
Change From Baseline in Left Ventricular Ejection Fraction
Time Frame
Baseline, Up to Year 1
Title
Change From Baseline in Left Ventricular Systolic Volume
Time Frame
Baseline, Up to Year 1
Title
Change From Baseline in Left Ventricular Wall Mass
Time Frame
Baseline, Up to Year 1
Title
Liver Substudy (Single Study Site Only): Change from Baseline to 6 Months in Hepatic Proton Density Fat Fraction (PDFF%), Assessed by 1H-Magnetic Resonance Spectroscopy (1H-MRS)
Time Frame
Baseline, Month 6
Title
Liver Substudy (Single Study Site Only): Change From Baseline to 6 Months in Creatine Kinase/Alanine Aminotransferase (CK/ALT)
Time Frame
Baseline, Month 6
Title
Liver Substudy (Single Study Site Only): Change From Baseline to 6 Months in Alanine Aminotransferase (ALT)
Time Frame
Baseline, Month 6
Title
Liver Substudy (Single Study Site Only): Change From Baseline to 6 Months in Aspartate Aminotransferase (AST)
Time Frame
Baseline, Month 6
Title
Annualized Frequency of Rhabdomyolysis and Cardiomyopathy-MCEs During the Double-blind Treatment Period
Time Frame
Up to Year 4
Title
Annualized Duration of Rhabdomyolysis, Cardiomyopathy, and Hypoglycemic-MCEs During the Double-blind Treatment Period
Time Frame
Up to Year 4
Title
Change From Baseline to EOS in Caregiver-reported Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scale Score for Participants 2 Years of Age or Older
Time Frame
Up to Year 4
Title
Change From Baseline to EOS in PedsQL Infant Scale Score for Participants Ages 1 to <24 Months
Time Frame
Up to Year 4
Title
Survival Time During the Double-blind Treatment Period
Time Frame
Up to Year 4
Title
Annualized Hospitalization Days During the Double-blind Treatment Period
Time Frame
Up to Year 4
Title
Number of Missed School or Learning Opportunity Days During the Double-blind Treatment Period
Time Frame
Up to Year 4
Title
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, and Adverse Events of Special Interest (AESIs)
Time Frame
Up to Year 4
Title
Number of Participants With TEAEs and Serious TEAEs Leading to Dose Modifications, Dose Reductions, Treatment Interruptions, Discontinuations From Study Drug, and Discontinuations From the Study
Time Frame
Up to Year 4
Title
Plasma Concentration Levels of Heptanoate
Time Frame
Up to Year 1
Title
Plasma Concentration Levels of Beta Hydroxypentanoate (BHP)
Time Frame
Up to Year 1
Title
Acceptability and Palatability Survey Scores of Triheptanoin Mixed with Oral Liquids
Time Frame
Up to Year 1

10. Eligibility

Sex
All
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria for Main Study: Males and females, from 0 (including newborns) to < 18 years of age Confirmed diagnosis of LC-FAOD Have a caregiver(s) willing and able to assist in all applicable study requirements Have a legally authorized representative willing and able to provide written informed consent after the nature of the study has been explained and prior to any research-related procedures, and the study participant to be able to provide age-appropriate written assent Have ANY ONE of the following significant clinical manifestations of LC-FAOD: At least 2 in the prior year, or 3 in the prior 2 years, of severe major episodes of metabolic decompensation (eg, hypoglycemia, rhabdomyolysis, or exacerbation of cardiomyopathy, requiring ER/urgent care unit visits or hospitalizations) Recurrent symptomatic hypoglycemia (clinical symptoms of hypoglycemia) requiring intervention Susceptibility to hypoglycemia after short periods of fasting (less than 4 to 12 hours, depending on age) Evidence of functional cardiomyopathy requiring ongoing medical management or clinical manifestation of heart failure Sibling(s) with the same pathogenic variant who presented with MCEs Participant with pathogenic variants that are known or suspected to be associated with absent or severely reduced enzyme activity or with severe disease manifestations. From the time of informed consent to 5 days after the last dose of study drug in this study, females of childbearing potential and fertile males must consent to use highly effective methods of contraception. If female, agree not to become pregnant. If male, agree not father a child or donate sperm Inclusion Criteria for Liver Substudy: Enrollment in the Main Study of Study UX007-CL302 Age > 2 years Liver fat content ≥ 2% and < 20% PDFF as assessed by 1 H-MRS Body mass index < 95th percentile Able to comply with instructions (remaining still during scan) and requirements (eg, constraints on recent meals, no metallic items or implanted devices in the body, no recent contrast agents) for liver 1 H-MRS scan Exclusion Criteria for Main Study: Enrolled in a clinical study involving concurrent use of an investigational drug product within 30 days before Screening Use of a prohibited medication (eg, valproate products or pancreatic lipase inhibitors) within 30 days before Screening, or unwilling to avoid a prohibited medication or other substance that may confound study objectives Treatment with triheptanoin within 60 days of Screening History of known hypersensitivity to triheptanoin or MCT Caregiver unwilling or unable to sign informed consent, or release of medical records, or follow study procedures Have any co-morbid conditions, including unstable major organ-system disease(s) that in the opinion of the Investigator places the subject at increased risk of complications, interferes with study participation or compliance, or confounds study objectives. History of metabolic decompensation(s) with metabolic acidosis, hyperammonemia, and/or liver enzyme elevations does not constitute an exclusion criterion unless in the opinion of the Investigator places the subject at increased risk of complications, interferes with study participation or compliance, or confounds study objectives Have a diagnosis of pancreatic insufficiency Pregnant, breastfeeding, or planning to become pregnant (self or partner) at any time during the study Exclusion Criteria for Liver Substudy: Acute or chronic liver disease other than LC-FAOD that presents with increased risk of liver fat (eg, hepatic cirrhosis, viral toxic or drug hepatitis, diabetes mellitus) and/or metabolic syndrome Need for anesthesia/sedation to perform liver 1 H-MRS
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Patients Contact: Trial Recruitment
Phone
(+1) 888-756-8657
Email
trialrecruitment@ultragenyx.com
First Name & Middle Initial & Last Name or Official Title & Degree
HCPs Contact: Medical Information
Phone
(+1) 888-756-8657
Email
medinfo@ultragenyx.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director
Organizational Affiliation
Ultragenyx Pharmaceutical Inc
Official's Role
Study Director
Facility Information:
Facility Name
General University Hospital in Prague-GUH (Všeobecná fakultní nemocnice v Praze- VFN)
City
Prague
ZIP/Postal Code
120-08
Country
Czechia
Individual Site Status
Recruiting
Facility Contact:
Phone
(+1)8887568657
Email
trialrecruitment@ultragenyx.com
First Name & Middle Initial & Last Name & Degree
Pavel Jesina
Facility Name
Universität Freiburg
City
Freiburg im Breisgau
ZIP/Postal Code
79106
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Phone
(+1)8887568657
Email
trialrecruitment@ultragenyx.com
First Name & Middle Initial & Last Name & Degree
Ute Spiekerkotter
Facility Name
Instytut Pomnik-Centrum Zdrowia Dziecka
City
Warszawa
State/Province
Mazowieckie
ZIP/Postal Code
04-730
Country
Poland
Individual Site Status
Not yet recruiting
Facility Contact:
Phone
(+1)8887568657
Email
trialrecruitment@ultragenyx.com
First Name & Middle Initial & Last Name & Degree
Dariusz Rokicki
Facility Name
Gdańksi Uniwersytet Medyczny
City
Gdańsk
State/Province
Pomorskie
ZIP/Postal Code
80-952
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
Phone
(+1)8887568657
Email
trialrecruitment@ultragenyx.com
First Name & Middle Initial & Last Name & Degree
Jolanta Wierzba
Facility Name
King Faisal Specialist Hospital & Research Centre
City
Riyadh
ZIP/Postal Code
11211
Country
Saudi Arabia
Individual Site Status
Not yet recruiting
Facility Contact:
Phone
(+1)8887568657
Email
trialrecruitment@ultragenyx.com
First Name & Middle Initial & Last Name & Degree
Moeenaldeen Al-Sayed
Facility Name
Sant Joan de Deu Hospital (SJD)
City
Barcelona
State/Province
Esplugues De Llobregat
ZIP/Postal Code
08950
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Phone
(+1)8887568657
Email
trialrecruitment@ultragenyx.com
First Name & Middle Initial & Last Name & Degree
Angels Garcia-Cazorla
Facility Name
University Hospital Santiago de Compostela
City
A Coruña
ZIP/Postal Code
15706
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Phone
(+1)8887568657
Email
trialrecruitment@ultragenyx.com
First Name & Middle Initial & Last Name & Degree
Maria Luz Couce Pico
Facility Name
University Hospital 12 de Octubre
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Phone
(+1)8887568657
Email
trialrecruitment@ultragenyx.com
First Name & Middle Initial & Last Name & Degree
Pilar Quijada Fraile
Facility Name
Gazi University
City
Ankara
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
Phone
(+1)8887568657
Email
trialrecruitment@ultragenyx.com
First Name & Middle Initial & Last Name & Degree
Fatih Ezgu
Facility Name
Ege University
City
Bornova-İzmir
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
Phone
(+1)8887568657
Email
trialrecruitment@ultragenyx.com
First Name & Middle Initial & Last Name & Degree
Sema Kalkan-Ucar
Facility Name
Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi
City
Istanbul
ZIP/Postal Code
34093
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
Phone
(+1)8887568657
Email
trialrecruitment@ultragenyx.com
First Name & Middle Initial & Last Name & Degree
Gulden Fatma Gokcay
Facility Name
Cerrahpasa Medical Faculty
City
Istanbul
ZIP/Postal Code
34116
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
Phone
(+1)8887568657
Email
trialrecruitment@ultragenyx.com
First Name & Middle Initial & Last Name & Degree
Ayse Cigdem Aktuglu Zeybek
Facility Name
Great Ormond Street Hospital
City
London
ZIP/Postal Code
WC1N 3JH
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
Phone
(+1)8887568657
Email
trialrecruitment@ultragenyx.com
First Name & Middle Initial & Last Name & Degree
Stephanie Grunewald

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
https://ultrarareadvocacy.com/conditions-we-study/long-chain-fatty-acid-oxidation-disorders-lc-faod/
Description
Ultragenyx Patient Advocacy/LC-FAOD Disease Information

Learn more about this trial

A Study to Determine the Effect of Triheptanoin Compared With Even-chain, MCT on MCEs in Pediatric Patients With LC-FAOD

We'll reach out to this number within 24 hrs